Advocacy intelligence hub — real-time data for patient organizations
Jagiellonian University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — NA
Fengming Kong — EARLY_PHASE1
Guangdong Provincial People's Hospital — NA
Barbara Ann Karmanos Cancer Institute — PHASE1
Nanfang Hospital, Southern Medical University — NA
IDEAYA Biosciences — PHASE1, PHASE2
Azedra Ultratrace: FDA approved
AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.
National Cancer Institute (NCI)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Azedra Ultratrace
Progenics Pharmaceuticals, Inc.
Azedra Ultratrace
(Iobenguane I 131)Orphan drugProgenics Pharmaceuticals, Inc.
Margaret von Mehren
Fox Chase Cancer Center
Vincent Chung, MD
City of Hope Medical Center
📍 DUARTE, CA
Stacey Cohen
Fred Hutch/University of Washington Cancer Consortium
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Dan Zandberg, MD, MD
UPMC Hillman Cancer Center
📍 BALTIMORE, MD
Rohit Joshi, MD, DDS
Cancer Research South Australia
📍 PHOENIX, AZ